Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 – a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein–like Receptor 1– on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction
Conclusion:
A single subcutaneous administration of SP16, a synthetic targeted LRP1 agonist, was safe and well-tolerated in patients with STEMI. A trend toward reduction in the inflammatory response and infarct size with SP16 was noted; however, the sample size for this study was not based on formal statistical criteria. More extensive studies are planned to determine the clinical efficacy of SP16 in STEMI.
NCT: NCT04225533.
Source: Journal of Cardiovascular Pharmacology - Category: Cardiology Tags: Drugs in the Pipeline: Original Article Source Type: research
More News: Angioplasty | Cardiology | Cardiovascular | Clinical Trials | Coronary Angioplasty | Drugs & Pharmacology | Heart | Heart Attack | History of Medicine | Percutaneous Coronary Intervention | Statistics | Study